Seroquel XR in Schizophrenia Relapse Prevention

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00990626
First received: October 1, 2009
Last updated: November 16, 2010
Last verified: November 2010

October 1, 2009
November 16, 2010
October 2009
July 2010   (final data collection date for primary outcome measure)
Rate of patients remained relapse free after 6 months of treatment [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00990626 on ClinicalTrials.gov Archive Site
  • Adherence rate of patients [ Designated as safety issue: No ]
  • Quality of Life (QoL ) [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Seroquel XR in Schizophrenia Relapse Prevention
Seroquel XR in Schizophrenia Relapse Prevention

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Psychiatric outpatient clinics

Schizophrenia Relapse Prevention
Not Provided
1
Schizophrenic outpatients
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1600
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion Criteria:

  • Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Hungary
 
NCT00990626
NIS-NHU-SER-2009/1
No
MC MD, AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Attila Németh National Psychiatric Centre
Study Chair: Lilla Szabó AstraZeneca Hungary MC
Study Director: Tamás Bábel AstraZeneca Hungary MC
AstraZeneca
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP